For further details see:
AbbVie taps priority review voucher to expand Rinvoq into ulcerative colitisFor further details see:
AbbVie taps priority review voucher to expand Rinvoq into ulcerative colitisMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Shares of AbbVie Inc. (NYSE: ABBV) traded at a new 52-week high today and are currently trading at $190.2. So far today, approximately 1.86M shares have been exchanged, as compared to an average 30-day volume of 5.03M shares. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceut...
AbbVie Completes Acquisition of Cerevel Therapeutics PR Newswire Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, ne...
Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day PR Newswire Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM ® Day on August 21, 2024 Members receive an exclusive gift card offer and ...